XMU-MP-1 attenuates osteoarthritis via inhibiting cartilage degradation and chondrocyte apoptosis

Xue Hao1,2,3†, Jing Zhao4†, Liyuan Jia4, Ting He5, Huanbo Wang6, Jing Fan6, Yating Yang1,2,3, Fei Su1,2,3, Qingda Lu1,2,3, Chao Zheng6, Liu Yang6 and Qiang Jie1,2,3*

1Pediatric Orthopaedic Hospital, Honghui Hospital, Xi’an Jiaotong University, Xi’an, China, 2Research Center for Skeletal Developmental Deformity and Injury Repair, School of Life Science and Medicine, Northwest University, Xi’an, China, 3Clinical Research Center for Pediatric Skeletal Deformity and Injury of Shaanxi Province, Xi’an, China, 4College of Life Sciences, Northwest University, Xi’an, China, 5Medical Research Institute, Northwestern Polytechnical University, Xi’an, China, 6Institute of Orthopedic Surgery, Xijing Hospital, Air Force Medical University, Xi’an, China

Osteoarthritis (OA) is the most prevalent type of degenerative joint disease; it is reported to be associated with inflammatory responses, chondrocyte apoptosis, and cartilage degeneration. XMU-MP-1 is a selective MST1/2 inhibitor which activates the downstream effector YAP and promotes cell growth. It has displayed excellent benefits in mouse intestinal repair, as well as liver repair and regeneration. However, the effects of XMU-MP-1 on OA remain unclear. In this study, we investigated the therapeutic role of XMU-MP-1 on interleukin-1β (IL-1β)-induced inflammation in mice chondrocytes and the destabilization of the medial meniscus surgery (DMM)-induced OA model. In chondrocytes, treatment with XMU-MP-1 elevated the matrix metalloproteinases (Mmp3, Mmp13) and decreased the extracellular matrix (Col2, Acan) induced by IL-1β. Moreover, XMU-MP-1 strongly inhibited IL-1β-induced chondrocyte apoptosis and significantly promoted chondrocyte proliferation. Furthermore, XMU-MP-1 demonstrated a protective and therapeutic influence on the mouse OA model. These findings indicate that XMU-MP-1 may have a protective effect on cartilage degradation and may be a new potential therapeutic option for OA.

KEYWORDS
osteoarthritis, XMU-MP-1, Hippo signaling, chondrocyte, cartilage

Introduction

Osteoarthritis (OA) is the most common joint disease, affecting more than 240 million persons worldwide (Global Burden of Disease Study 2013 Collaborators, 2015). Patients with OA live with severe joint pain, stiffness, and significantly reduced mobility, leading to decreased productivity and life quality, as well as there being an increased economic burden to patients and society (Litwic et al., 2013). However, current
treatments for OA include pain amelioration and eventual joint replacement for end-stage disease, and lack an effective disease-modifying approach (Cao et al., 2020). The discovery of new treatment strategies for OA is urgently needed.

OA is a disorder disease involving the whole joint, with pathologic changes in cartilage, bone, synovium, ligament, muscle, and periarticular fat, among which the progressive destruction of articular cartilage is one of the main pathological manifestations (Sharma, 2021). The articular cartilage is a flexible tissue composed of extracellular matrix and chondrocytes; it provides an optimal surface to enable movements in the joint, prevents friction between the bones, and facilitates the transmission of loading to the underlying bone. Chondrocytes are the only cells in cartilage, synthesizing extracellular matrix to maintain cartilage homeostasis and thus preserving the structural and functional integrity of the cartilage (He Y. et al., 2020). During OA pathogenesis, risk factors such as aging and aberrant mechanical stress stimuli result in altered chondrocyte functioning in cartilage maintenance, and an imbalance of chondrocyte anabolism and catabolism (Hunter and Bierma-Zeinstra, 2019). Additionally, an increased level of apoptosis was observed in OA cartilage, resulting in decreased living chondrocytes and enhanced extracellular matrix degradation (Hwang and Kim, 2015). Therefore, an approach that integrates chondrocyte anabolism-catabolism homeostasis maintenance and chondrocyte apoptosis reduction provides a clue for a promising OA treatment.

Hippo signaling is an evolutionarily conserved pathway that plays a pivotal role in organ-size control by balancing cell proliferation and death; it consists of a core kinase cascade and downstream transcriptional effector (Yin and Zhang, 2011). Ste20-like kinases 1/2 (MST1/2) are the key components of the Hippo signaling pathway. The kinase cascade is composed of MST1/2, SAV1, LATS1/2, and MOB1A/B which conducts cellular signals to subsequently phosphorylate Yes-associated protein (YAP) and sequester YAP in the cytoplasm (Wu et al., 2003; Huang et al., 2005; Pan, 2007). When Hippo signaling is inactive, YAP translocates into nuclei, forming a complex with TEA domain transcription factor (TEADs) to promote the transcription of pro-proliferation and pro-survival genes (Wu et al., 2008; Zhang et al., 2008). Furthermore, recent studies have found that Hippo-YAP signaling plays an important role in chondrocyte maintenance and cartilage degeneration (Deng et al., 2018; Fu et al., 2019; Li et al., 2022). YAP alleviates senescence via up-regulation of FOXD1 (Fu et al., 2019) and attenuates NF-κB signaling by direct interaction with TAK1 in regulating matrix-degrading enzyme expression and cartilage degradation in OA pathogenesis (Deng et al., 2018). Considering the promoting effects of YAP on cell proliferation, the modulation of Hippo-YAP signaling activity may present a viable strategy for treating OA.

The small molecular compound XMU-MP-1 is a potent and selective inhibitor of MST1/2 that activates the downstream effector YAP, promoted cell growth and augmenting liver and intestinal repair and regeneration (Fugin et al., 2016). However, the effects of XMU-MP-1 in OA pathogenesis remain unclear.

In the present study, we identified XMU-MP-1 as a compound with effects of anti-cartilage degeneration using in vitro and in vivo OA models. In cultured chondrocytes, a supplement of XMU-MP-1 rescued the elevation of catabolic factors, and the decrease of extracellular matrix synthesis induced by IL-1β treatment. Moreover, XMU-MP-1 strongly inhibited IL-1β-induced chondrocyte apoptosis and significantly promoted chondrocyte proliferation. Furthermore, XMU-MP-1 exhibited a protective and therapeutic influence on mice OA models. The mechanism study uncovered the crucial role of YAP in XMU-MP-1 protective effects in OA pathogenesis. In summary, these findings indicate that XMU-MP-1 may exert protective effects on cartilage degradation and may be a new potential therapeutic option for OA.

Materials and methods

Animals

All animal work performed in this study was approved by the Ethics in Animal Research Committee of the Air Force Medical University. In accordance with the standards for animal housing, mice were group-housed at 23°C–25°C with a 12-hour light/dark cycle and allowed free access to water and standard laboratory pellets.

To induce OA, male mice 8 weeks of age were subjected to DMM surgery or sham surgery at the right knee as described previously (Glasson et al., 2007). Briefly, in DMM surgery, the joint capsule was opened immediately after anesthesia, and the medial meniscotibial ligament was cut to destabilize the meniscus without damaging other tissues. In sham surgery, the joint capsule was opened in the same fashion but without any further damage.

For administration in mice, XMU-MP-1 was dissolved in DMSO (stock concentration, 5 mg/ml), diluted in corn oil by 1:10 before injection. Six weeks after DMM surgery, the mice received treatment intraperitoneally every other day for 2 weeks with XMU-MP-1 (1 mg/kg). Solution of 10% DMSO with 90% corn oil was used as a negative control. Mice were euthanized 2 months after surgery.

Histology analyses

Mouse joints were fixed with 4% paraformaldehyde overnight, decalcified with 10% EDTA for 7 days, embedded in O.C.T. compound, and sectioned using a frozen slicer. The sections were stained with haematoxylin and eosin (H&E) and Safranin O/Fast Green to analyze phenotypic changes within the knee joint. Images were captured with an Olympus microscope. The articular cartilage destruction was quantified using the
established Osteoarthritis Research Society International (OARSI) scoring system (score: 0–6) (Pritzker et al., 2006).

**Immunofluorescence**

Immunostaining was performed according to the standard protocol.

For immunofluorescence analysis of the cartilage, frozen sections were incubated with antibodies specific for YAP (1:100, 14074; Cell Signaling), TAZ (1:100, 83669; Cell Signaling), MST1 (1:100, MA5-13026; ThermoFisher), and MMP13 (1:100, 18165-1-AP; proteintech) overnight at 4°C and then incubated with Cy3-conjugated secondary antibody (1:1000, BA1031, BA1032; BOSTER) for 1 h.

For immunofluorescence analysis of the primary chondrocytes, cells were fixed with 4% paraformaldehyde for 10 min, then incubated in 0.3% Triton X-100 for 15 min, blocked by blocking buffer (1% bovine serum albumin in PBS) for 15 min, and incubated with antibodies specific for YAP (1:100, 14074; Cell Signaling) and Collagen II (1:100, MA5-13026; ThermoFisher) and were then incubated with Cy3-conjugated secondary antibody (1:1000, BA1031, BA1032; BOSTER) for 1 h.

Images were captured with a laser-scanning confocal microscope (OLYMPUS FV1000) using the FV10-ASW 4.2 Viewer (OLYMPUS) and analyzed using ImageJ software.

**Primary chondrocyte extract, culture and treatment**

For primary culture of chondrocytes, rib cartilage was isolated from P0-3 pups and digested with collagenase D solution (3 mg/ml, Roche) for 1 h at 37°C under 5% CO2 in a thermal incubator. Tissue fragments were agitated several times to detach soft tissues and then digested for 4 h at 37°C. The digestion solution was retrieved, filtered through a 45 μm cell strainer and then centrifuged for 5 min at 1,000 rpm. The pellet was re-suspended with DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco), 50 U per ml penicillin and 0.05 mg per ml streptomycin. The chondrocytes were seeded at a density of 2 × 10⁴ cells per cm² and cultured under sterile conditions at 37°C under 5% CO₂. Only the first passage cells were used for experiments.

For experiments, the chondrocytes were treated with 1 ng/ml recombinant murine IL-1β (P10749; PEPROTECH) for 48 h in the presence or absence of XMU-MP-1 (S8334; Selleck).

**siRNA transfection**

Duplex siRNA targeting Yap was purchased from GenePharma. When cells grew to 60%–70% density, siRNAs were transfected into cells in vitro with Lipofectamine RNAiMAX (Invitrogen) in accordance with the manufacturer’s instructions, followed by treatment of IL-1β and/or XMU-MP-1 for 48 h.

The sequences were as follows: siRNA-control: UUCUCC GAACGUGUCAGUTT; siRNA-Yap: GGUCAAAGAUAC GGUCAAAGAUAC.

**Micromass culture and alcian blue staining**

For micromass culture, chondrocytes (4 × 10⁵ cells in 20 μl) were dropped into round droplets in wells of a four-well chamber slide (SPL-30404; Bio-Arrow), waiting for attachment at 37°C for 4 h, then supplemented with 500 μl cell culture medium and cultured for 3 days. After treatment of IL-1β and/or XMU-MP-1 for 48 h, the cells were subjected to Alcian blue staining. The micromass cultures were washed with PBS three times, then fixed at room temperature for 15 min in 4% paraformaldehyde, and stained with Alcian blue solution (1.0% Alcian blue in 0.1 N HCl) for 4 h; ddH₂O washes were performed until no color was visible in the supernatant. Images were acquired with a Zeiss microscope.

**RNA extraction and quantitative RT-PCR**

Total RNA was extracted from cultured chondrocytes with MiniBEST Universal RNA Extraction Kit (9767; Takara) according to manufacturer’s instructions, and the cDNAs were synthesized using ReverTra Ace qPCR RT Master Mix with gDNA Remover (FSQ-301; TOYOBO). Real-time PCR was performed using the SYBR Green Real-time PCR Master Mix (QPK-201; TOYOBO) reagent with the BioRAD CFX96 System. Results were repeated for three independent biological replicates. Gapdh was used as a normalized control. The sequence of PCR primers used in the study were listed in Supplementary Table S1.

**EdU staining**

To access the proliferation of chondrocytes, EdU staining assay was utilized using BeyoClick™ EdU Cell Proliferation Kit with Alexa Fluor 555 (C0075S; Beyotime). Images were captured with a laser-scanning confocal microscope (OLYMPUS FV1000) using the FV10-ASW 4.2 Viewer (OLYMPUS), then analyzed using ImageJ software. Five random visions per sample were chosen to capture the images.

**Flow cytometry analysis**

The apoptosis of the chondrocytes was evaluated by flow cytometry analysis. The cells were stained using the FITC
Statistical analysis

Statistical analysis was performed with GraphPad Prism software, and the results were given as mean ± SEM. Differences between experimental groups were assessed using the unpaired two-tailed Student’s t-test or one-way ANOVA with Bonferroni post hoc test: * is \( p < 0.05 \), ** is \( p < 0.01 \), *** is \( p < 0.001 \), **** is \( p < 0.0001 \), and “ns” is no significance with \( p > 0.05 \).

Results

Hippo signaling is hyper-activated in OA chondrocytes

Since much research on the role of Hippo-YAP signaling in OA pathogenesis has had no clear conclusion (Zhong et al., 2013; Karystionou et al., 2015; Deng et al., 2018; Goto et al., 2018; Fu et al., 2019; Gong et al., 2019; Zhang Q. et al., 2019; Zhang X. et al., 2019; He J. et al., 2020; Li et al., 2022), we first investigated the Hippo signaling activity change in OA cartilage chondrocytes. DMM surgery was used to recapitulate the degenerative condition of articular cartilage in mice joint. Two months after surgery, the articular cartilage degeneration could be observed by Safranin O/Fast Green fluorescence staining of type II collagen in chondrocytes treated by IL-1\( \beta \) or/and XMU-MP-1 consistently suggested that degradation of extracellular matrix induced by IL-1\( \beta \) treatment was inhibited by XMU-MP-1 (Figures 2D,E). Damaged chondrogenesis usually includes reduced cartilage matrix synthesis and enhanced cartilage matrix degradation (Moon-Chang et al., 2019). Accordingly, IL-1\( \beta \) treatment led to increased expression of matrix degrading enzymes and decreased expression of ECM components. We examined expression of matrix degrading enzymes \( Mmp3 \) and \( Mmp13 \), and ECM components \( Collagen \ II \) and \( Aggrecan \) at mRNA levels to address the role of XMU-MP-1 in cartilage matrix maintenance. As shown in Figure 2F, compared with the IL-1\( \beta \)-treated group, co-treatment with XMU-MP-1 restored decrease of \( Collagen \ II \) and \( Aggrecan \) expression, accompanied with the inhibition of elevated \( Mmp3 \) and \( Mmp13 \) expression. Furthermore, different dosages (5 \( \mu \)M or 25 \( \mu \)M) of XMU-MP-1 resulted in similar effects in catabolic factor suppression, while various conditions of treatment suggested that XMU-MP-1 functions in a time-dependent manner (Supplementary Figures S2A,B). Taken together, these results indicate that treatment of XMU-MP-1 results in the activation of YAP in OA chondrocytes and serves chondroprotective functions.

Protective effects of XMU-MP-1 on ECM degradation and chondrogenesis

Based on our results, we propose that restoring YAP in OA chondrocytes might have chondroprotective effects against arthritis. The small molecular compound XMU-MP-1 was identified as a selective inhibitor of MST1/2 that enhanced downstream YAP activation and exhibited \textit{in vivo} efficacy in liver and intestinal repair and regeneration (Fuqin et al., 2016). Thus, here comes up with our hypothesis that XMU-MP-1 may be a potentially effective drug against OA. We first investigated whether XMU-MP-1 was capable of restoring YAP in IL-1\( \beta \) treated chondrocytes. As shown in Figures 2A,B, co-treatment of XMU-MP-1 rescued the downregulation of YAP expression induced by IL-1\( \beta \). Micromass culture was then employed to monitor the protective effects of XMU-MP-1 on chondrogenesis. Alcian Blue staining of the micromass cultures showed that exposure to IL-1\( \beta \) resulted in impaired chondrogenesis, while supplementing with XMU-MP-1 recovered the damaged chondrogenesis (Figure 2C). Immunofluorescence staining of type II collagen in chondrocytes treated by IL-1\( \beta \) or/and XMU-MP-1 consistently suggested that degradation of extracellular matrix induced by IL-1\( \beta \) treatment was inhibited by XMU-MP-1 (Figures 2D,E). Damaged chondrogenesis usually includes reduced cartilage matrix synthesis and enhanced cartilage matrix degradation (Moon-Chang et al., 2019). Accordingly, IL-1\( \beta \) treatment led to increased expression of matrix degrading enzymes and decreased expression of ECM components. We examined expression of matrix degrading enzymes \( Mmp3 \) and \( Mmp13 \), and ECM components \( Collagen \ II \) and \( Aggrecan \) at mRNA levels to address the role of XMU-MP-1 in cartilage matrix maintenance. As shown in Figure 2F, compared with the IL-1\( \beta \)-treated group, co-treatment with XMU-MP-1 restored decrease of \( Collagen \ II \) and \( Aggrecan \) expression, accompanied with the inhibition of elevated \( Mmp3 \) and \( Mmp13 \) expression. Furthermore, different dosages (5 \( \mu \)M or 25 \( \mu \)M) of XMU-MP-1 resulted in similar effects in catabolic factor suppression, while various conditions of treatment suggested that XMU-MP-1 functions in a time-dependent manner (Supplementary Figures S2A,B). Taken together, these results indicate that treatment of XMU-MP-1 results in the activation of YAP in OA chondrocytes and serves chondroprotective functions.

XMU-MP-1 facilitates proliferation and suppresses apoptosis of OA chondrocytes

Previous studies have demonstrated that OA chondrocytes exhibit reduced proliferation and increased apoptosis. Combined with the role of Hippo-YAP signaling in regulating cell proliferation and apoptosis, we surmised that XMU-MP-1 offers unique advantages in manipulating OA chondrocyte proliferation and...
FIGURE 1
Hippo signaling is hyper-activated in OA chondrocytes. (A) Representative images of Safranin O/Fast Green staining of knee joint sections from wild-type mice which underwent sham or DMM surgery for 8 weeks. (B) Representative images of knee joint sections from wild-type mice which underwent sham or DMM surgery for 8 weeks. Sections were immunostained with antibody against YAP (red or gray) and DAPI (nuclei, blue). Panels on the right are high magnifications of boxed regions in the left panels. The dashed lines marked the edge of cartilage. (C) Statistical analysis of (Continued)
apoptosis. EdU labeling experiments were carried out to explore the function of XMU-MP-1 in chondrocyte proliferation regulation. As shown in Figures 3A,B, suppressed proliferation of chondrocytes induced by IL-1β treatment was rescued by co-treatment of XMU-MP-1. Additionally, Flow cytometry analysis showed that XMU-MP-1 restored increased cell apoptosis induced by IL-1β in chondrocytes (Figures 3C,D). Further mechanism study revealed that XMU-MP-1 treatment promoted the expression of Ctgf, Cyr61, and Survivin, which are responsible for cell proliferation and apoptosis regulation (Figure 3E). As described above, these results suggest that XMU-MP-1 facilitates proliferation and suppresses apoptosis of OA chondrocytes.

**XMU-MP-1 attenuates OA pathogenesis**

Following to the above results, we explored the role of XMU-MP-1 in OA pathogenesis in vivo. DMM surgery was carried out to successfully establish the mouse OA model that articular cartilage degeneration could be observed in Safranin O/Fast Green staining, as well as a decrease in the ratio of thickness of hyaline cartilage to calcified cartilage (HC/CC) (Figure 4). As previously described, XMU-MP-1 exhibited favorable pharmacokinetics with a half-life of 1.2 h, and a minimal dose of 1 mg/kg via intraperitoneal injection (Fușin et al., 2016). Therefore, we administered XMU-MP-1 via intraperitoneal injection with a frequency of once every other day from 6 weeks after DMM surgery for two more weeks (Supplementary Figure S3A). To address the concern that systemic administration of XMU-MP-1 may cause unexpected side effects, the weight curve of mice along the treatment was monitored. No detectable difference in weight between control and treatment groups indicated no obvious harm to health (Supplementary Figure S3B). To evaluate the protective effects of XMU-MP-1 on cartilage degeneration, haematoyxin and eosin (H&E) and Safranin O/Fast Green staining were performed to evaluate the histomorphological differences. The OARSI score, based on the histological features of OA progression, provides an overall assessment of cartilage OA status, including depth of progression and the extent of surface area affected (Wenzel et al., 2016). Compared with the vehicle group, administration of XMU-MP-1 suppressed erosion on the articular cartilage surfaces, synovial thickening, and restored the OARSI score and HC/CC ratio (Figure 4). Mechanistically, decrease of ECM components (type II collagen) and elevated expression of matrix degradation enzyme MMP13 in OA cartilage induced by DMM surgery were also blocked by XMU-MP-1 (Figure 5), indicating decreased matrix degradation—consistent with the results from cultured chondrocytes. Taken together, these results demonstrate that XMU-MP-1 attenuates articular cartilage degeneration during OA pathogenesis.

**YAP plays a crucial role in XMU-MP-1 chondroprotective function during OA pathogenesis**

We next investigated the underlying mechanism of the protective effects of XMU-MP-1 on cartilage degeneration during the OA process. Firstly, the expression of YAP and MST1 in cartilage chondrocytes from the vehicle or XMU-MP-1 treatment groups were examined. As expected, administration of XMU-MP-1 restored the increase of MST1 and decrease of YAP in cartilage chondrocytes (Figure 6). Since we noticed that the expression of YAP changed more obviously than MST1, we hypothesized—accompanied by the present view that YAP is a downstream effector of MST1/2 in Hippo signaling—that YAP plays a crucial role in XMU-MP-1 chondroprotective functions. Yap siRNA was transfected in chondrocytes to knockdown YAP. As shown in Figure 7A, inhibition of Mmp3 and Mmp13 by XMU-MP-1 treatment were partially de-repressed in Yap depleted chondrocytes. EdU labeling experiments showed suppressed cell proliferation by Yap knockdown upon XMU-MP-1 stimulation (Figures 7B,C). Additionally, Flow cytometry analysis showed that decreased apoptosis by XMU-MP-1 treatment was blocked by YAP depletion (Figures 7D,E). Altogether, these results demonstrate that XMU-MP-1 attenuates cartilage degeneration via regulating matrix degradation and chondrocyte proliferation-apoptosis balance in a YAP-dependent manner.

**Discussion**

The articular cartilage is a highly differentiated tissue lacking blood vessels for nutrition supply, leading to...
FIGURE 2
Protective effects of XMU-MP-1 on ECM degradation and chondrogenesis. (A) Representative images of cultured primary chondrocytes treated with IL-1β or/and XMU-MP-1 for 48 h. Cells were immunostained with antibody against YAP (red). (B) Statistical analysis of relative fluorescence of YAP in cultured chondrocytes in A. n = 3, 3, 3, 3. (C) Representative images of chondrocyte micromass cultures treated with IL-1β or/and XMU-MP-1 for 48 h. The micromass cultures were subjected to Alcian blue staining. (D) Representative images of cultured primary chondrocytes treated with IL-1β or/and XMU-MP-1 for 48 h. Cells were immunostained with antibody against COLII (red). (E) Statistical analysis of relative fluorescence of COLII in D. n = 3, 3, 3, 3. (F) Relative mRNA levels of Mmp3, Mmp13, Col2, and Acan in primary chondrocytes treated with IL-1β or/and XMU-MP-1 for 48 h. All data are presented as mean ± SEM. ns p > 0.05, **p < 0.01, ***p < 0.001.
FIGURE 3
XMU-MP-1 facilitates proliferation and suppresses apoptosis of OA chondrocytes. (A) Representative images of EdU labeling chondrocytes treated with IL-1β or/and XMU-MP-1 for 48 h. EdU (5-ethynyl-2'-deoxyuridine) was added during cell culture and subsequently stained with a fluorescent dye (red) and DAPI (nuclei, blue). (B) Statistical analysis of the EdU+ chondrocytes numbers in B. (C) Representative flow cytometry graphs of cultured primary chondrocytes stained with Annexin V-FITC and propidium iodide (PI) treated with IL-1β or/and XMU-MP-1 for 48 h. (D) Statistical analysis of apoptotic cells in B. (E) Relative mRNA levels of YAP target genes Ctgf, Cyr61, and Survivin in chondrocytes treated with IL-1β or/and XMU-MP-1 for 48 h. All data are presented as mean ± SEM. ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001.
FIGURE 4
XMU-MP-1 alleviates articular cartilage degeneration during OA process. (A) Representative images of HE staining of knee joint sections from mice of indicated groups. SHAM: Mice underwent sham surgery. Vehicle: Mice undergoing DMM surgery were intraperitoneally injected with vehicle. XMU-MP-1: Mice undergoing DMM surgery were intraperitoneally injected with XMU-MP-1. Panels in the middle are high magnifications of boxed regions in the left panels; panels on the right are high magnifications of boxed regions in the middle panels. (B) Representative images of (Continued)
irreversibility in cartilage degradation and difficulty in the effective disease-modified therapy of OA. An approach combining anabolism-catabolism homeostasis maintenance and chondrocyte apoptosis reduction may promise an OA treatment. In this study, we identified compound XMU-MP-1 as a potential therapeutic agent to moderate OA cartilage...
degeneration. Cultured primary chondrocytes were exposed to IL-1β to induce inflammation and simulate OA phenotype in vitro, resulting in an imbalance of chondrocyte anabolism and catabolism and increased apoptosis, which were restored by co-treatment of XMU-MP-1. Additionally, administration of XMU-MP-1 in mice via intraperitoneal injection alleviated DMM-induced cartilage degeneration. Further mechanism study revealed that XMU-MP-1 exerts chondroprotective effects in a YAP-dependent manner. As well as the research on promoting the effects of XMU-MP-1 in liver and intestine recovery and regeneration, our work demonstrates for the first time that XMU-MP-1 may exert a protective effect on cartilage degradation and serve as a new potential therapeutic option for OA.

Chondrocytes are the only cells sparsely distributed in the extracellular matrix in cartilage. Thus, their survival is important for proper cartilage matrix maintenance; compromising chondrocyte function and survival will lead to articular cartilage failure. It has been previously reported that, in OA cartilage, 18%–21% of chondrocytes showed apoptotic features, compared with 2%–5% in normal cartilage (Heraud et al., 2000). Chondrocyte death leads to the failure of cartilage homeostasis maintenance (Hwang and Kim, 2015). It is notable that the Hippo signaling pathway...
FIGURE 7
YAP plays a crucial role in XMU-MP-1 chondroprotective function during OA pathogenesis. (A) Relative mRNA levels of Yap, Mmp3, and Mmp13 in primary chondrocytes transfected with the control or Yap siRNA, treated with IL-1β or/and XMU-MP-1. (B) Representative images of EdU labeling chondrocytes transfected with the control or Yap siRNA, treated with IL-1β or/and XMU-MP-1. Cells stained with a fluorescent dye (red) and DAPI (nuclei, blue). (C) Statistical analysis of the EdU+ chondrocytes numbers in B. (D) Representative flow cytometry graphs in primary chondrocytes transfected with the control or Yap siRNA, treated with IL-1β or/and XMU-MP-1. (E) Statistical analysis of apoptotic cells in D. All data are presented as mean ± SEM. ns p > 0.05, *p < 0.05.
exerts a critical role in cell proliferation and apoptosis by modulating the transcription of target genes (Zheng and Pan, 2019). MST1/2 inhibitor XMU-MP-1 takes advantage of Hippo-YAP signaling in cell proliferation and apoptosis regulation. In the present work, we revealed the anti-apoptotic and pro-proliferation function of XMU-MP-1 on OA chondrocyte in a YAP-dependent manner.

As well as apoptosis, impaired ECM catabolism also contributes to OA. Catabolism of the cartilage ECM is partially mediated by a variety of degradative enzymes, including matrix metalloproteinases (MMPs) and ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs), by which both collagen fibrils and proteoglycans are degraded (JA et al., 2001; Glasson et al., 2005). However, clinical trials that directly target catabolic enzymes met with limited success and have resulted in side effects including musculoskeletal pain and inflammation (Cao et al., 2020). In recent decades, numerous mechanism studies regulating cartilage degradation and chondrocyte maintenance have been performed to explore therapeutic targets. Several signaling pathways—such as NF-κB signaling, Wnt signaling, and Hippo-YAP signaling—have been proved critical for OA pathogenesis (Moon-Chang et al., 2019; Wang et al., 2019; Zarka et al., 2021). However, current studies investigating the role of Hippo-YAP signaling in the OA process mainly focus on YAP, rather than on other core components of Hippo signaling, in modulating chondrocyte maintenance and cartilage degradation (Deng et al., 2018; Zhang X. et al., 2019; Fu et al., 2019). In the present study, knockdown of Yap by siRNA in chondrocytes partially abolished the XMU-MP-1 protective effects on extracellular matrix degradation induced by IL-1β treatment; this indicates the possibility of YAP-independent mechanisms. Several studies have unveiled the engagement of MST1/2 in the regulation of the innate immune independence of the canonical effectors YAP/TAZ. For instance, the induction of mitochondria trafficking and reactive oxygen species (ROS) is impaired in Mst1/2 deficient phagocytes after bacterial infection (Geng et al., 2015). Together with these findings, our mechanism study results raise the possibility of MST1/2 in cartilage matrix catabolism via non-canonical Hippo signaling cascade.

On the other hand, the role of YAP in OA is still under debate. Besides the anti-inflammatory role of YAP mediated by interaction with TAK1 in OA cartilage chondrocytes, YAP is also demonstrated to serve as a mechanotransducer of chondrocytes on chondrocyte-phenotype maintenance (Deng et al., 2018; Zhang X. et al., 2019). This raises the concern that activation of YAP by XMU-MP-1 treatment may lead to chondrocyte dedifferentiation and failure in cartilage matrix maintenance. Given the fact that XMU-MP-1 is a selective inhibitor of MST1/2, one of numerous kinases undertaking transduction of the cellular signaling via phosphorylation of downstream YAP/TAZ, activation of YAP by XMU-MP-1 is quite mild—no such phenomenon of ECM destruction or chondrocyte dedifferentiation in XMU-MP-1 treated micromass cultures was observed in the present study (Figure 2C).

As the sole population existing in cartilage, the poor reproducing capacity of chondrocytes impairs cartilage regeneration. Our work demonstrated that XMU-MP-1 promotes chondrocyte proliferation, which will benefit future bio-material research on cartilage regeneration. Together with its role in anti-apoptosis and cartilage matrix maintenance, XMU-MP-1 may serve as a promising therapeutic option for OA.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**Ethics statement**

The animal study was reviewed and approved by the Ethics in Animal Research Committee of the Air Force Medical University.

**Author contributions**

XH, LY, and QJ: designed the experiments; XH, JZ, LJ, TH, and HW: performed the experiments; XH, YY, FS, and QL: performed the measurements, analysis, and data validation; XH and JZ: drafted the manuscript; LY and QJ: revised the manuscript; XH, LJ, CZ, LY, and QJ: funding acquisition.

**Funding**

This research was financially supported by the National Natural Science Foundation of China (82002351, 81871743, 82130070, 82002261, 82002361), China Postdoctoral Science Foundation (2021M693891), Key Research and Development Program of Shaanxi (2025SF-026), Scientific Research Project of Xi’an Health Commission (2021ms12), Innovation Team Projects—Innovation Capability Support Program of Shaanxi Province (2020TD-036), and Clinical Medical Research Center Projects—Innovation Capability Support Program of Shaanxi Province (2020LCZX-03). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2022.998077/full#supplementary-material
growth-regulatory pathway. *Dev. Cell* 14, 388–398. doi:10.1016/j.devcel.2008.01.007

Yin, M., and Zhang, L. (2011). Hippo signaling: A hub of growth control, tumor suppression and pluripotency maintenance. *J. Genet. Genomics* 38, 471–481. doi:10.1016/j.jgg.2011.09.009

Zarka, M., Hay, E., and Cohen-Solal, M. (2021). Yap/taz in bone and cartilage biology. *Front. Cell Dev. Biol.* 9, 788773. doi:10.3389/fcell.2021.788773

Zhang, L., Ren, F., Zhang, Q., Chen, Y., Wang, B., and Jiang, J. (2008). The tead/tet family of transcription factor scalloped mediates Hippo signaling in organ size control. *Dev. Cell* 14, 377–387. doi:10.1016/j.devcel.2008.01.006

Zhang, Q., Fang, X., Zhao, W., and Liang, Q. (2019a). The transcriptional coactivator Yap1 is overexpressed in osteoarthritis and promotes its progression by interacting with beclin-1. *Gene* 689, 210–219. doi:10.1016/j.gene.2018.11.068

Zhong, W., Li, Y., Li, L., Zhang, W., Wang, S., and Zheng, X. (2013). Yap-mediated regulation of the chondrogenic phenotype in response to matrix elasticity. *J. Mol. Histol.* 44, 587–595. doi:10.1007/s10735-013-9502-y